Working to build a world without Fentanyl deaths
We are a team of researchers, clinicians and biotech executives with a strong track record in substance abuse and CNS with multiple commercial exits
Mark E. Pearson - Co-Founder & Board Member
Mark is the Founder and CEO of Altamont Pharma Holdings as well as a General Partner of Annex Ventures. Mark has been investing in startup Life Science and Technology companies for over 20 years.
Mark is the Co-Founder and Vice Chairman of the Board of Drawbridge Realty, a San Francisco based real estate development and investment company, which owns over 6 million square feet of commercial real estate leased to Technology and Life Science companies predominantly in the western United States. Drawbridge Realty's portfolio exceeds $2.5 billion in asset value. In December 2014, Drawbridge Realty formed a partnership with international asset management firm Kohlberg Kravis Roberts & Co, LP (“KKR”) which made a significant investment in the company to substantially grow the platform.
Mark is the Co-Founder and Vice Chairman of the Board of Drawbridge Realty, a San Francisco based real estate development and investment company, which owns over 6 million square feet of commercial real estate leased to Technology and Life Science companies predominantly in the western United States. Drawbridge Realty's portfolio exceeds $2.5 billion in asset value. In December 2014, Drawbridge Realty formed a partnership with international asset management firm Kohlberg Kravis Roberts & Co, LP (“KKR”) which made a significant investment in the company to substantially grow the platform.
John D. Harkey, Jr. - Co-Founder & Board Member
Mr. Harkey was Co-Founder and formerly Executive Chairman of the Board of AveXis, Inc. (NASDAQ:AVXS), acquired by Novartis in 2018 for $8.7 billion), which develops proprietary gene therapies for rare neurological genetic diseases. John has over 25 years of experience as a private investor, chief executive and director in both public and private companies. He has merged, acquired, operated and/or served on the board of directors of eight public companies in biotech, energy, technology, aerospace, telecom and restaurants, and private companies in healthcare, real estate, farm and ranch products and software. He previously served nine years on the Board of Directors of the Baylor Health Care System Foundation.
Board
of
Directors
Jay Shepard - Board Member
Mr. Shepard served as Executive Chairman of Versartis, Inc., from December 2013 to 2015. In May 2015, Mr. Shepard joined Versartis as President and CEO. In 2018, Versartis merged with Aravive (NASDAQ: ARAV), and he served as the President and Chief Executive Officer from May 2018 to January 2020, when he retired.
Sharon Tetlow - Board Member
Ms. Tetlow has served as Managing Partner of Potrero Hill Advisors since January 2016. Potrero Hill Advisors provides strategic and operational financial support to life science companies through its team of chief financial officers and controllers.
Ms. Tetlow was previously the Managing Director of Danforth Advisors from April 2013 to January 2016. She served as Chief Financial Officer of Pathwork Diagnostics, Inc, a privately held biotechnology company, from 2011 to 2013. From 2005 to 2009, she served as Chief Financial Officer of Cell Genesys, Inc.(CEGE) a publicly traded biotechnology company.
Ms. Tetlow was previously the Managing Director of Danforth Advisors from April 2013 to January 2016. She served as Chief Financial Officer of Pathwork Diagnostics, Inc, a privately held biotechnology company, from 2011 to 2013. From 2005 to 2009, she served as Chief Financial Officer of Cell Genesys, Inc.(CEGE) a publicly traded biotechnology company.
Daniel Fine - Board Member
Daniel Fine is currently Managing Director of West Summit Investments, in Dallas, Texas. West Summit is a private investment company with an emphasis on biotech and interests in banking and real estate. Over the previous 10 years, Mr. Fine was a Director and EVP of two-family offices with a focus on Real Estate, Oil and Gas, and Private Equity investing. Prior to the private investment business, he spent six years working for the Hicks Sports Marketing Group as the Vice President of Sales for the Texas Rangers Baseball Club and Senior Vice President of the Dallas Stars Hockey Club.
In Memoriam: Dr. David Genecov, M. D. - Co-Founder, Former Chief Medical Officer & Board Member
Dr. David Genecov is a dedicated physician in the field of cleft lip and palate, craniofacial and pediatric plastic surgery. David has over 25 years of experience as a practicing surgeon, private investor, chief executive and director in both public and private companies. Dr. Genecov was Co-Founder and former director of AveXis, Inc. (NASDAQ: AVXS), acquired by Novartis in 2018 for $8.7 billion, which develops proprietary gene therapies for rare neurological genetic diseases. David also founded or co-founded numerous companies in the health care industry, including Skin Within, Inc., Synergy Surgical Services LLC, Biolife Cell Bank LLC and is the owner and director of The Modern Medical Spa. He was a director and investor of CerSci Therapeutics, a pharmaceutical company using non opioid approaches to treat pain, which was sold to Acadia Pharmaceuticals (NASDAQ: ACAD) in 2020 for up to $940 million. David is a director and co-founder of Cessation Therapeutics, Inc., a company based on the treatment of substance use disorders with monoclonal antibodies and vaccines. Currently, Dr. Genecov serves as the President and CEO of Dialectic Therapeutics, Inc., a Dallas-based precision oncology company using innovative new protein degradation technologies to treat cancer.
Mark E. Pearson - Co-Founder & Board Member
Mark is the Founder and CEO of Altamont Pharma Holdings as well as a General Partner of Annex Ventures. Mark has been investing in startup Life Science and Technology companies for over 20 years.
Mark is the Co-Founder and Vice Chairman of the Board of Drawbridge Realty, a San Francisco based real estate development and investment company, which owns over 6 million square feet of commercial real estate leased to Technology and Life Science companies predominantly in the western United States. Drawbridge Realty's portfolio exceeds $2.5 billion in asset value. In December 2014, Drawbridge Realty formed a partnership with international asset management firm Kohlberg Kravis Roberts & Co, LP (“KKR”) which made a significant investment in the company to substantially grow the platform.
Mark is the Co-Founder and Vice Chairman of the Board of Drawbridge Realty, a San Francisco based real estate development and investment company, which owns over 6 million square feet of commercial real estate leased to Technology and Life Science companies predominantly in the western United States. Drawbridge Realty's portfolio exceeds $2.5 billion in asset value. In December 2014, Drawbridge Realty formed a partnership with international asset management firm Kohlberg Kravis Roberts & Co, LP (“KKR”) which made a significant investment in the company to substantially grow the platform.
John D. Harkey, Jr. - Co-Founder & Board Member
Mr. Harkey was Co-Founder and formerly Executive Chairman of the Board of AveXis, Inc. (NASDAQ:AVXS), acquired by Novartis in 2018 for $8.7 billion), which develops proprietary gene therapies for rare neurological genetic diseases. John has over 25 years of experience as a private investor, chief executive and director in both public and private companies. He has merged, acquired, operated and/or served on the board of directors of eight public companies in biotech, energy, technology, aerospace, telecom and restaurants, and private companies in healthcare, real estate, farm and ranch products and software. He previously served nine years on the Board of Directors of the Baylor Health Care System Foundation.
Board
of
Directors
Jay Shepard - Board Member
Mr. Shepard served as Executive Chairman of Versartis, Inc., from December 2013 to 2015. In May 2015, Mr. Shepard joined Versartis as President and CEO. In 2018, Versartis merged with Aravive (NASDAQ: ARAV), and he served as the President and Chief Executive Officer from May 2018 to January 2020, when he retired.
Sharon Tetlow - Board Member
Ms. Tetlow has served as Managing Partner of Potrero Hill Advisors since January 2016. Potrero Hill Advisors provides strategic and operational financial support to life science companies through its team of chief financial officers and controllers.
Ms. Tetlow was previously the Managing Director of Danforth Advisors from April 2013 to January 2016. She served as Chief Financial Officer of Pathwork Diagnostics, Inc, a privately held biotechnology company, from 2011 to 2013. From 2005 to 2009, she served as Chief Financial Officer of Cell Genesys, Inc.(CEGE) a publicly traded biotechnology company.
Ms. Tetlow was previously the Managing Director of Danforth Advisors from April 2013 to January 2016. She served as Chief Financial Officer of Pathwork Diagnostics, Inc, a privately held biotechnology company, from 2011 to 2013. From 2005 to 2009, she served as Chief Financial Officer of Cell Genesys, Inc.(CEGE) a publicly traded biotechnology company.
Daniel Fine - Board Member
Daniel Fine is currently Managing Director of West Summit Investments, in Dallas, Texas. West Summit is a private investment company with an emphasis on biotech and interests in banking and real estate. Over the previous 10 years, Mr. Fine was a Director and EVP of two-family offices with a focus on Real Estate, Oil and Gas, and Private Equity investing. Prior to the private investment business, he spent six years working for the Hicks Sports Marketing Group as the Vice President of Sales for the Texas Rangers Baseball Club and Senior Vice President of the Dallas Stars Hockey Club.
In Memoriam: Dr. David Genecov, M. D. - Co-Founder, Former Chief Medical Officer & Board Member
Dr. David Genecov is a dedicated physician in the field of cleft lip and palate, craniofacial and pediatric plastic surgery. David has over 25 years of experience as a practicing surgeon, private investor, chief executive and director in both public and private companies. Dr. Genecov was Co-Founder and former director of AveXis, Inc. (NASDAQ: AVXS), acquired by Novartis in 2018 for $8.7 billion, which develops proprietary gene therapies for rare neurological genetic diseases. David also founded or co-founded numerous companies in the health care industry, including Skin Within, Inc., Synergy Surgical Services LLC, Biolife Cell Bank LLC and is the owner and director of The Modern Medical Spa. He was a director and investor of CerSci Therapeutics, a pharmaceutical company using non opioid approaches to treat pain, which was sold to Acadia Pharmaceuticals (NASDAQ: ACAD) in 2020 for up to $940 million. David is a director and co-founder of Cessation Therapeutics, Inc., a company based on the treatment of substance use disorders with monoclonal antibodies and vaccines. Currently, Dr. Genecov serves as the President and CEO of Dialectic Therapeutics, Inc., a Dallas-based precision oncology company using innovative new protein degradation technologies to treat cancer.